Company / Depreciation & Amortization
Xeris Biopharma Holdings, Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.3M
FY2025
5-year range
$1.2M / $1.5M
FY2021-FY2025
Trend
+7.0%
vs FY2024
Sector context
#117 of 168
Health Care
What the data says
At $1M, Xeris Biopharma Holdings, Inc.'s depreciation & amortization ranks #52 of 168 in the Health Care sector. Improved from $1M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -2.2%.
Improved from $1M to $1M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -0.4%
- 5-Year CAGR
- -2.2%
- 10-Year CAGR
- -
Sector benchmark
#52 of 168 in Health CareTop 30% of 168This company $1.3M Sector average $212.9M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.2%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 7.0% year-over-year.
- Ranks #117 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | +7.0% |
| FY2024 | $1.2M | -17.5% |
| FY2023 | $1.5M | +11.9% |
| FY2022 | $1.3M | +0.0% |
| FY2021 | $1.3M | -9.4% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026